A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs AT 527 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept
- Sponsors Atea Pharmaceuticals
- 12 Apr 2018 Results presented in the Atea pharmaceuticals media release.
- 12 Apr 2018 According to an Atea pharmaceuticals media release, data from this trial will be presented at the at The International Liver Congress 2018.
- 25 Jul 2017 New trial record